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ABSTRACT 
Dipeptidyl peptidase-4 (DPP-4) inhibitors are diabetes mellitus drugs that inhibit the metabolism of glucagon-
like peptide-1 (GLP-1) from the DPP-4 enzyme thus prolong the half-life of GLP-1. This review provides an 
overview of DPP-4 inhibitors from triterpenes and steroids and some related compounds from in silico 
prediction, in vitro, and in vivo studies. The knowledge of the heterogeneity of DPP-4 inhibitors structure from 
synthetic drugs as well as natural sources will assist to design more potential DPP-4 inhibitors, yet it is needed 
to be evaluated clinically. Hopefully, the scientific combination among molecular modelling and experimental 
studies perspectives will generate DPP-4 inhibitors with the desired outcome. 
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INTRODUCTION 
Diabetes mellitus (DM) is a chronic disease associated with metabolic disorder syndrome in 
carbohydrate, protein, and fat1. Diabetes mellitus type 2 is more predominant than diabetes mellitus 
type 1. In 2014, about 422 million people diagnosed with DM and this prevalence increased almost 
four times compared to 19802. In 2040, the International Diabetes Federation estimates that 642 
million people will live with DM3. Diabetes mellitus might affect all ages and all countries. The 
youngest child in the world to be diagnosed with DM type 2 is 3 year old4. The prevalence of DM in 
developing countries also increases faster than in developed countries. 
DM is a chronic disease that can induce microvascular and macrovascular complications. 
Microvascular complications including neuropathy, nephropathy, and retinopathy whilst 
macrovascular complications such as a coronary artery, peripheral artery, disease, and stroke. The 
primary goal of diabetes mellitus therapy is the combination of changing the lifestyle and medicines 
treatment to reduce the manifestation of more serious complications, decrease mortality, and increase 
the quality of life5,6. Current medicines to treat diabetes mellitus such as sulfonylureas and 
thiazolidinediones tend to induce hypoglycemia and weight gain5. As maintaining body weight is one 
of the diabetes mellitus goal therapy, a new medicine which does not induce weight gain is needed. 
A relatively new diabetes mellitus therapy, DPP-4 inhibitors, was firstly released in October 2006 
based on its pathophysiology. The discovery of the DPP-4 inhibitor was initiated in the early 1900s 
where the administration of oral glucose produces higher incretin hormone than via intravenous route, 
indicating glucose stimulation on β cell pancreas. The incretin, intestinal secretion insulin, consisted 
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of two predominant hormones, glucose-dependent insulinotropic (GIP) and GLP-1. The concentration 
of GIP hormone in diabetic patient type 2 is common, has minimal effect on glucagon suppression, 
and does not enhance insulin secretion. On the contrary, GLP-1 hormone has low concentration, 
decreases glucagon release, and sensitive to stimulate insulin. However, the limitation of the GLP-1 
hormone is its short half-life of around two minutes due to the degradation by an enzyme called DPP-
4. By blocking the DPP-4 enzyme, it can maximize the potential of GLP-1 to stimulate insulin thus 
reduce postprandial blood glucose7-9. Therefore, DPP-4 inhibitors are being developed and pursued. 
Moreover, treatment of DPP-4 inhibitors as single therapy or combination is reported weight 
neutrality in DM type 2 patients10. 
The popularity of ethnomedicine to prevent or cure diseases has been known widely due to low toxic 
effects and minimum cost than modern medicines11. By 2018, the trending market for herbals 
supplements has been increased 9.4% from 2017 in the United States. In 2018, people spent 8.8 
billion USD in total for supplement, while the demand for triterpenes and steroids are  estimated 
around 12.4 billion USD yearly12-13. Since the use of traditional plants especially triterpenes, steroids, 
and some related compounds show promising efficacy, this review presents triterpenes steroids and 
related structures of DPP-4 inhibitors. 
EXPERIMENTAL 
Structure of DPP-4 Inhibitors by In-silico  
Binding Site according to Cyanopyrrolidine Structure 
The structure of DPP-4 inhibitors are heterogeneous and summarized in Fig.-1. Marvaniya and 
Patel14 proposed that there were two requirements for cyanopyrrolidines to interact with the DPP-4 
enzyme. First, it was suggested that the inhibitors of DPP-4 have nitrile in the scissile bond. A bond 




Fig.-1:Heterogeneity of DPP-4 inhibitors Structure 
 
The nitrile in the scissile bond will bind with serine (Ser630) in the catalytic site of the receptor to 
form a covalent bond and act as competitive inhibitors. Second, hydrogen bonding between 
protonated inhibitor compounds and the negative charge of the surface receptor. Three amino acid 
residues in the region which are negatively charged are Glu205, Glu206, and Tyr662. The removal of 
amine group will decrease the potency common protonated region from DPP-4 inhibitors is amine. 
Nevertheless, the removal of amine group will decrease the potency. Sitagliptin, alogliptin, 
linagliptin, and tenegliptin make salt bridges with Glu205 and Glu20616. 
Substitution of methylsulfonamide analog in omarigliptin led this drug to have the longest half-life 
among other DPP-4 inhibitors and it only takes once a week dosing17. Also, Arulmozhiraja et al14 
proposed that Trp629 and Tyr547 amino acids are important in S2’ pocket (Table-1) and interaction 
with Tyr666 and Phe357 are significant to make hydrophobic bond. Lai et al18 investigated that the 
potency of linagliptin is higher than alogliptin due to interaction with Trp629 and Tyr547. 
 
  Vol. 14 | No. 1 |149-154| January - March | 2021 
HETEROGENEITY OF TRITERPENES AND STEROIDS                                                                                             K. Budipramana et al. 151 
Table-1: Amino Acid Residues of DPP-4 Pocket 
Pocket Amino Acids Residues Inhibitor Class of DPP-4 











S2 Arg125  Arg669  Glu205 Glu206 Phe357 Arg358  
S1’ Tyr547 Tyr631 Phe357 Pro550 Tyr666     
S2’ Trp629 His740 Ser630 Tyr547      
 
Moreover, DPP-4 inhibitor compounds which can interact with S2 extensively have advantages as 
their selectivity enhances as well as their potency19. Maladkar and co-workers20 classified DPP-4 
inhibitors into 3 classes according to their interaction with DPP-4 pocket (Table-1).  
Structure-activity Relationship of Triterpenes and Steroids and Some related Compounds In-silico 
Geng et al21 examined 12 purified fractions guided as a DPP-4 inhibitor from Inonotus obliquus. This 
purified fraction contains 19 compounds according to their UPLC-QTOF-MS spectra. As seen in Fig.-
2, five compounds (1, 2, 5, 13, and 14) were predicted as the active compounds that responsible for 
DPP-4 inhibitors based on energy binding that almost the same as that sitagliptin as the positive 
control. 
Three compounds (1, 2, 5) from top five compounds contain amino group with diverse structure and 
two compounds (13 and 14) were triterpenes and steroid derivates. Compound 1 (-113.391 kJ/mol) 
and 2 (-105.071 kJ/mol) showed lower binding energy compared to sitagliptin (-90.2814 kJ/mol). The 
lower binding energy means the higher ability of inhibitor compounds to bind the receptor 
spontaneously to form a more stable interaction22, hence suggests more potential than sitagliptin as 
DPP-4 inhibitors. From the molecular modelling, compound 1 gives lower binding energy compared 
to compound 2. Although this result is similar to Marvaniya and Patel14, yet it still needs to be 
evaluated in vitro, in vivo, or even in clinical studies. 
 
 
Fig.-2: All the Compounds were obtained from a Fraction guided by DPP-4 Inhibitor 
RESULTS AND DISCUSSION 
Structure of DPP-4 Inhibitors by In-vitro and In-vivo Approach  
Terpenoids are composed of isoprene units mostly reported from higher plants. According to the 
isoprene rule, triterpenoids are categorized from monoterpenoids (C10) to polyterpenoids (> 
C40)23,24. Due to their widely varied structure terpenoid display various biological activities from to 
anti-cancer, anti-inflammation, immunomodulators, and anti-diabetic even it can be utilized in 
cosmetics, food, and perfume23-30.  
In Fig.-3, we summarized various triterpenes and steroids reported from some previous studies that 
had been examined using in vitro and in vivo assay for DPP-4 inhibitor. We compared IC50 of 
triterpenes or steroids which contain amino groups in their structure31-33. It reveals that triterpenes or 
steroids as aglycone such as stigmasterol (15), lupeol (16), and quinovic acid (17) have IC50 >100; 
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31.6; and 30.7 µM, respectively. In aglycones, their structure differ in the cyclic ring, olefin position, 
side chains, and the presence of carboxylic acid. Compound (17) has 2 carboxylic acids and gives 
similar IC50 to that of (16) which has no carboxylic acid. In contrast to (16), stigmasterol (15) give 
IC50 more than 100 µM.  
 
 
Fig.-3: The Diverse Structure of Triterpenes and Steroids as DPP-4 Inhibitors. 
 
Compound (19) is a glycoside of quinovic acid (17). The addition of 1 glycoside, quinovic acid-3β-O-
β-D-glycopyranoside (19), led to the increase of IC50 to 57.8 µM compared to its aglycone. However, 
the addition of two glycosides in quinovic acid-3β-O-β-D-glycopyranosyl-(28à1)- β-D-
glucopyranosyl ester showed IC50 23.5 µM. In many reports, triterpenes or steroids glycoside have 
higher solubility compared to the triterpenes or steroids aglycones. This perhaps due to the addition of 
glycosyl, hydroxyl, acyl can increase their polarity23,26. This profile can also be seen in stigmasterol 
aglycone (15) and its derivate, 3-O-stigmasterol-(6-O-palmitoyl)-b-D-glucopyranoside (18), that the 
IC50 of its glycoside from dropped to 16.58 µM. 
Oleanolic acid (22), a pentacyclic triterpene, was reported to have IC50 1.21 µM. The methyl 
esterification of carboxylic acid (23) and oxidation of alcohol into ketone can decrease IC50 to 0.091 
µM. However, the total modification of 22 into 23 produces a more suitable compound to bind the 
DPP-4 enzyme. Compounds 22 and 23 also have been examined in diabetic mice to reduce serum 
glucose34. They also modified oleanolic acid into six derivatives to produce compounds 23-28. 
Compounds 24-28 contain pyridine ring and/or morpholine ring. The addition of the pyridine ring 
(24-25) gave lower IC50 values than in addition to the morpholine ring (27-28) while the combination 
addition of pyridine and morpholine ring gave the lowest IC50 of 0.0044 µM (26) to inhibit the DPP-
4 enzyme. Compound 26 was also claimed effective to inhibit PPARγ enzyme with IC50 0.0078 
µM34. In contrast to oleanolic acid, bevirimat (21), was tested using in vitro assay and showed no 
inhibitory effect on DPP-433. 
CONCLUSION 
This finding suggested that the heterogeneity of triterpenes and steroids structure could act as a DPP-4 
inhibitor. In finding novel DPP-4 inhibitor compounds, total design and modification predicted 
inhibitor compounds should be confirmed with in vivo studies and clinical studies. 
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